Literature DB >> 26551782

Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.

L Angenendt1, C Schliemann1, M Lutz1, E Rebber1, A B Schulze1, M Weckesser2, L Stegger2, M Schäfers2, C Groth1, T Kessler1, G Lenz1, M Stelljes1, W E Berdel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26551782     DOI： 10.1038/bmt.2015.266

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  14 in total

Review 1.  Immune checkpoint blockade in hematologic malignancies.

Authors:  Philippe Armand
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

2.  Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.

Authors:  Karl S Peggs; Ann Hunter; Rajesh Chopra; Anne Parker; Premini Mahendra; Donald Milligan; Charles Craddock; Ruth Pettengell; Ahmet Dogan; Kirsty J Thomson; Emma C Morris; Geoff Hale; Herman Waldmann; Anthony H Goldstone; David C Linch; Stephen Mackinnon
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

3.  Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

Authors:  Mizuki Nishino; Lynette M Sholl; F Stephen Hodi; Hiroto Hatabu; Nikhil H Ramaiya
Journal:  N Engl J Med       Date:  2015-07-16       Impact factor: 91.245

Review 4.  Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!

Authors:  M A Kharfan-Dabaja; M Hamadani; H Sibai; B N Savani
Journal:  Bone Marrow Transplant       Date:  2014-01-20       Impact factor: 5.483

5.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

7.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Craig H Moskowitz; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Alessandro M Gianni; Angelo Carella; Dzhelil Osmanov; Veronika Bachanova; John Sweetenham; Anna Sureda; Dirk Huebner; Eric L Sievers; Andy Chi; Emily K Larsen; Naomi N Hunder; Jan Walewski
Journal:  Lancet       Date:  2015-03-19       Impact factor: 79.321

Review 8.  Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.

Authors:  Robert R Jenq; Marcel R M van den Brink
Journal:  Nat Rev Cancer       Date:  2010-02-19       Impact factor: 60.716

9.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

10.  Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients.

Authors:  Stefanie Sauer; Paola A Erba; Mario Petrini; Andreas Menrad; Leonardo Giovannoni; Chiara Grana; Burkhard Hirsch; Luciano Zardi; Giovanni Paganelli; Giuliano Mariani; Dario Neri; Horst Dürkop; Hans D Menssen
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113
View more
  23 in total

1.  Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection.

Authors:  Mitra Bhattacharyya; Pablo Penaloza-MacMaster
Journal:  AIDS Res Hum Retroviruses       Date:  2018-04-18       Impact factor: 2.205

Review 2.  Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.

Authors:  Reid W Merryman; Philippe Armand
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

3.  Association between GvHD and nivolumab in the FDA adverse event reporting system.

Authors:  Y Oshima; T Tanimoto; K Yuji; A Tojo
Journal:  Bone Marrow Transplant       Date:  2017-07-31       Impact factor: 5.483

Review 4.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

5.  MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD.

Authors:  A-M Boekstegers; F Blaeschke; I Schmid; V Wiebking; S Immler; F Hoffmann; K Bochmann; S Müller; T G P Grünewald; J Feucht; T Feuchtinger
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

6.  PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.

Authors:  J C Albring; S Inselmann; T Sauer; C Schliemann; B Altvater; S Kailayangiri; C Rössig; W Hartmann; J R Knorrenschild; K Sohlbach; C Groth; M Lohoff; A Neubauer; W E Berdel; A Burchert; M Stelljes
Journal:  Bone Marrow Transplant       Date:  2016-11-28       Impact factor: 5.483

Review 7.  Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.

Authors:  Awais Ijaz; Ali Younas Khan; Saad Ullah Malik; Warda Faridi; Muhammad Asad Fraz; Muhammad Usman; Muhammad Junaid Tariq; Seren Durer; Ceren Durer; Atlantis Russ; Nadia Nunes Cavalcante Parr; Zeeshan Baig; Fnu Sagar; Zeeshan Ali; Ali McBride; Faiz Anwer
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-06       Impact factor: 5.742

8.  Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.

Authors:  A K Singh; L F Porrata; O Aljitawi; T Lin; L Shune; S Ganguly; J P McGuirk; S Abhyankar
Journal:  Bone Marrow Transplant       Date:  2016-04-25       Impact factor: 5.483

9.  PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Authors:  Bradley M Haverkos; Diana Abbott; Mehdi Hamadani; Philippe Armand; Mary E Flowers; Reid Merryman; Manali Kamdar; Abraham Sebastian Kanate; Ayman Saad; Amitkumar Mehta; Siddhartha Ganguly; Timothy S Fenske; Parameswaran Hari; Robert Lowsky; Leslie Andritsos; Madan Jagasia; Asad Bashey; Stacey Brown; Veronika Bachanova; Deborah Stephens; Shin Mineishi; Ryotaro Nakamura; Yi-Bin Chen; Bruce R Blazar; Jonathan Gutman; Steven M Devine
Journal:  Blood       Date:  2017-05-03       Impact factor: 22.113

Review 10.  Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction.

Authors:  Vaia Florou; Sonam Puri; Ignacio Garrido-Laguna; Breelyn A Wilky
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.